Ergotism, once an epidemic disease, is now a rare disorder. The most common manifestation is acute peripheral ischemia due to vasospasm,1 with an incidence of 0.001%.2 We report a case of a middle-age woman who presented with ergotamine-induced leg ischemia, due to chronic use of ergotamine-containing medications for migraine headaches. The diagnosis was confirmed with arteriography results, and she responded well to vasodilator therapy. The pharmacology, clinical presentation, diagnostic approach, and therapy of ergotism are reviewed.
Paraskevopoulos J., Teasdale D., Cuschieri R.: Severe reversible arterial spasm with ergotamineBr J Clin Pract49:214, 1995.
3.
Goodman RL, Gilman JB (eds): The Pharmacological Basis of Therapeutics , 9thed. New York: McGraw-Hill, 1995, pp 491-493.
4.
Hemingway D. : Ergot poisoning with multisystem involvementMilit Med10:257-260, 1965.
5.
Silberstein S.: The Pharmacology of ergotamine and dihydroergotamineHeadache37(suppl1):S15-S25, 1997.
6.
Merhoff G., Porter J.: Ergot intoxication: Historical review and description of unusual clinical manifestationsAnn Surg180:773, 1974.
7.
Meyler W.: Side effects of ergotamine: ReviewCephalalgia16:5-10, 1996.
8.
Muller-Schweinitzer E., Rosenthaler J.: Dihydro-ergotamine : Pharmacokinetics, pharmacodynamics and mechanism of venoconstrictor action in beagle dogsJ Cardiovasc Pharmacol9:686-693, 1987.
9.
Ibraheem J., Paalzow L., Tfelt-Hansen P.: Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferersEur J Clin Pharmacol23:235-240, 1982.
10.
Tfelt-Hansen P.: The effect of ergotamine on the arterial system in manActa Pharmacol Toxicol (Copenh) 59(suppl 3) :1-30, 1986.
11.
Muller-Schweinitzer E.: In vitro studies on the duration of action of dihydroergotamineInt J Clin Pharmacol18:88-91, 1980.
12.
Faberger S., Jorulf H., Sanderg C.: Ergotism, arteriospastic disease and recovery, studied angiographicallyActa Med Scand182:769-772, 1967.
13.
Fukui S., Coggia M., Goeau-Brissonniere O.: Acute upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillinAnn Vasc Surg11:420-424, 1997.
14.
Hayton A.: Precipitation of acute ergotism by triacetyloendomycinNZ Med J69:42-50, 1969.
15.
Venter C., Joubert P., Buys A.: Severe peripheral ischemia during concomitant use of beta-blockers and ergot alkaloidsBr Med J289:288-289, 1984.
16.
Enge I., Sivertssen E.: Ergotism due to therapeutic doses of ergotamine tartrateAm Heart J70:665-670, 1965.
17.
Cairols M., Gimenez A., Sieyro F., et al: Intoxicacion ergotaminica. Dos casos de ischemia perifericaAngiologia (Spain) 4:148-152, 1991.
18.
Bagby R., Cooper R.: Angiography in ergotism. Report of two cases and review of the literatureAm J Roentgenol Radium Ther Nucl Med116:179-186, 1972.
19.
Pader E.: Leriche syndrome in a patient with prolonged and continuous use of ergot derivativesVasc Dis4:380-388, 1967.
20.
Weaver R., Phillips M., Vacek J.: St. Anthony's Fire: A medieval disease in modern times: Case historyAngiology40:929-932, 1989.
21.
Mathey D., Montz R., Hanrath P., et al: Non-invasive method for recognition of coronary artery spasm: 201 thallium sequential scintigraphy of the myocardium after ergotamine provocationDtsch Wochenschr105:509-515, 1980.
Greene F., Ariyan S., Stansel H.: Mesenteric and peripheral vascular ischemia secondary to ergotismSurgery81:176-179, 1977.
25.
Ritcher A., Banker V.: Carotid ergotism. A complication of migraine therapyRadiology106:339-340, 1973.
26.
Lazarides M. , Karageorgiou C., Tsiara S., et al: Severe facial ischemia caused by ergotismJ Cardiovasc Surg33:383-385, 1992.
27.
Tarnower A. , Alguire P.: Ergotism masquerading as arteritisPostgrad Med J85:103-108, 1989.
28.
Tfelt-Hansen P., Olesen J.Arterial response to ergotamine tartrate in abusing and nonabusing migraine patientsActa Pharmacol Toxicol48:69-72, 1981.
29.
Curry R., Yalamanchili R.: Recurrent ergotism: A case reportJ Fam Pract6:769-773, 1978.
30.
Bongard O., Bounameaux H.: Severe iatrogenic ergotism : Incidence and clinical importanceVASA20:153-156, 1991.
31.
Diege-Petersen H., Lassen N., Tonnensen K., et al: Subclinical ergotismLancet2:65-66, 1977.
32.
Tfelt-Hansen P., Eickhoff J., Olesen J.: The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: Methodological aspects and time effect curveActa Pharmacol Toxicol47:151-156, 1980.
33.
Wells K., Steed D., Zajko A., et al: Recognition and treatment of arterial insufficiency from cafergotJ Vasc Surg4:8-15, 1986.
Kermerer V. , Daghen F., Pais S.: Successful treatment of ergotism with nifedipineAm J Roentgenol143:333-334, 1984.
36.
Piquemal R. , Emmerich J., Guilmot J., et al: Successful treatment of ergotism with iloprost: A case reportAngiology49:493-497, 1998.
37.
Shifrin E., Olschwang D., Perel A., et al: Reversal of ergotamine-induced arteriospasm by mechanical intraarterial dilatationLancet13:1278-1279, 1980 .
38.
Lepantalo M. , Rosenberg P., Pohjola J., et al: Epidural spinal cord stimulation in the treatment of limb threatening vasospasm—report of a case with a five-year follow-upEur J Vasc Endovasc Surg11:368-370, 1996.
